FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Market Closed - Börse Stuttgart 20:41:47 07/06/2024 BST | ||
| 12.22 EUR | -2.40% |
|
| Current month | -1.93% | ||
| 1 month | +3.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 12.22 | -2.40% |
| 06/06/24 | 12.52 | +0.32% |
| 05/06/24 | 12.48 | -0.16% |
| 04/06/24 | 12.5 | -0.87% |
| 03/06/24 | 12.61 | +1.20% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 08:41 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Morgan Stanley |
| WKN | MG1VJE |
| ISIN | DE000MG1VJE4 |
| Date issued | 08/04/2024 |
| Strike | 85.14 $ |
| Maturity | Unlimited |
| Parity | 1.56 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.01 € |
|---|---|
| Lowest since issue | 9.89 € |
| Spread | 0.02 € |
| Spread % | 0.16% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.7
USD
Average target price
82.7
USD
Spread / Average Target
+27.82%
- Stock Market
- Certificates
- Certificat